Non-invasive Prenatal Testing and the Unveiling of an Impaired Translation Process

Journal of Obstetrics and Gynaecology Canada

Volumn 39, Issue 1, 2017, Pages 10-17

  Murdoch, Blake ^a   Ravitsky, Vardit ^b   Ogbogu, Ubaka ^a   Ali Khan, Sarah ^c   Bertier, Gabrielle ^d,e   Birko, Stanislav ^b   Bubela, Tania ^a   De Beer, Jeremy ^f   Dupras, Charles ^b   Ellis, Meika ^a,f   Granados Moreno, Palmira ^d   Joly, Yann ^d   Kamenova, Kalina ^g   Master, Zubin ^h   Marcon, Alessandro ^a   Paulden, Mike ^a   Rousseau, François ⁱ   Caulfield, Timothy ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e Faculté de Médecine Centre Hospitalo universitaire   (France)

^f UNIVERSITY OF OTTAWA   (Canada)

^g TRENT UNIVERSITY   (Canada)

^h ALBANY MEDICAL COLLEGE   (United States)

ⁱ LAVAL UNIVERSITY   (Canada)

Author keywords

Commercialization; ethics; gynaecology; obstetrics; prenatal screening

Indexed keywords

ARTICLE; CANADA; DIAGNOSTIC VALUE; ECONOMIC DEVELOPMENT; FUNDING; HUMAN; MEDICAL ETHICS; NON INVASIVE PRENATAL TESTING; OBSTETRICS; PREGNANT WOMAN; PRENATAL DIAGNOSIS; PRENATAL SCREENING; REPRODUCTIVE HEALTH; SPONTANEOUS ABORTION; FEMALE; LEGISLATION AND JURISPRUDENCE; MATERNAL SERUM SCREENING TEST; PREGNANCY; TECHNOLOGY; TRANSLATIONAL RESEARCH; TRENDS;

FEMALE; HUMANS; MATERNAL SERUM SCREENING TESTS; OBSTETRICS; PREGNANCY; TECHNOLOGY TRANSFER; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85005877125     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jogc.2016.09.004     Document Type: Article

References (100)

1. 1 Lewis, C., Hill, M., Silcock, C., Daley, R., Chitty, L.S., NIPT for trisomy 21: a cross sectional survey of service users' views and likely uptake. Br J Obstet Gynaecol 121 (2014), 582–594.
2. 2 Brady, P., Brison, N., Van Den Bogaert, K., de Ravel, T., Peeters, H., Van Esch, H., et al. Clinical implementation of NIPT - technical and biological challenges. Clin Genet 89 (2015), 523–530 Available at: http://onlinelibrary.wiley.com/doi/10.1111/cge.12598/abstract Accessed on April 15, 2016.
3. 3 Lewis, C., Choudhury, M., Chitty, L.S., Hope for safe prenatal gene tests: a content analysis of how the UK press media are reporting advances in non-invasive prenatal testing. Prenat Diagn 35 (2014), 420–427.
4. 4 Kamenova, K., Ravitsky, V., McMullin, S., Caulfield, T., Media portrayal of non-invasive prenatal testing: a missing ethical dimension. Sci Comm 15:A03 (2016), 1–19.
5. 5 Allyse, M., Minear, M.A., Berson, E., Sridhar, S., Rote, M., Hung, A., et al. Non-invasive prenatal testing: a review of international implementation and challenges. Int J Womens Health 7 (2015), 113–126.
6. 6 Minear, M.A., Lewis, C., Pradhan, S., Chandrasekharan, S., Global perspectives on clinical adoption of NIPT. Prenat Diagn 35 (2015), 959–967.
7. 7 Farrell, R.M., Agatisa, P.K., Mercer, M.B., Mitchum, A., Coleridge, M., The use of noninvasive prenatal testing in obstetric care: educational resources, practice patterns, and barriers reported by a national sample of clinicians. Prenat Diagn 36 (2016), 499–506 Available at: http://onlinelibrary.wiley.com/doi/10.1002/pd.4812/abstract Accessed on April 15, 2016.
8. 8 Song, K., Musci, T.J., Caughey, A.B., Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Med 26 (2013), 1180–1185.
9. 9 Okun, N., Teitelbaum, M., Huang, T., Dewa, C.S., Hoch, J.S., The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. Prenat Diagn 34 (2014), 350–356.
10. 10 Benn, P., Curnow, K.J., Chapman, S., Michalopoulos, S.N., Hornberger, J., Rabinowitz, M., An economic analysis of cell-free DNA non-invasive prenatal testing in the US general pregnancy population. PLoS One, 10, 2015, e0132313.
11. 11 Dondorp, W., de Wert, G., Bombard, Y., Bianchi, N.W., Bergmann, C., Borry, P., et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. Eur J Hum Genet 23 (2015), 1438–1450.
12. 12 Gekas, J., Langlois, S., Ravitsky, V., Audibert, F., van den Berg, D.G., Haidar, H., Non-invasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical issues. Appl Clin Genet 9 (2016), 15–26.
13. 13 Yaron, Y., The implications of non-invasive prenatal testing failures: a review of an under-discussed phenomenon. Prenat Diagn 36 (2016), 391–396.
14. 14 Faas, B.H., Prenatal genetic care: debates and considerations of the past, present and future. Expert Opin Biol Ther 15 (2015), 1101–1105.
15. 15 Caulfield, T., Ogbogu, U., The commercialization of university-based research: balancing risks and benefits. BMC Med Ethics, 16, 2015, 70.
16. 16 Norton, M.E., Rose, N.C., Benn, P., Noninvasive prenatal testing for fetal aneuploidy: clinical assessment and a plea for restraint. Obstet Gynecol 121 (2013), 847–850.
17. 17 Lo, Y.M., Corbetta, N., Chamberlain, P.F., Rai, V., Sargent, I.L., Redman, C.W., et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350 (1997), 485–487.
18. 18 Norwitz, E.R., Levy, B., Noninvasive prenatal testing: the future is now. Rev Obstet Gynecol 6 (2013), 48–62.
19. 19 Swift D. Navigating the new world of non-invasive prenatal testing. The Medical Post Upfront (Canadian Health Care Network). 2014;8–9.
20. 20 Perinatal Services BC. Non-invasive prenatal testing (NIPT). Available at: http://www.perinatalservicesbc.ca/health-professionals/professional-resources/screening/prenatal-genetic/non-invasive-prenatal-testing-(nipt). Accessed on April 15, 2016.
21. 21 Children's Hospital of Eastern Ontario (CHEO) (2016). Frequently asked questions: non-invasive prenatal testing (NIPT). Available at: http://www.cheo.on.ca/en/NIPT. Accessed on March 22, 2016.
22. 22 Langlois, S., Brock, J.A., Current status in non-invasive prenatal detection of Down syndrome, trisomy 18, and trisomy 13 using cell-free DNA in maternal plasma. J Obstet Gynaecol Can 35 (2013), 177–181.
23. 23 Norton, M.E., Jacobsson, B., Swamy, G.K., Laurent, L.C., Ranzini, A.C., Brar, H., et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 372 (2015), 1589–1597.
24. 24 Audibert, F., Gagnon, A., Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies. Joint SOGC-CCMG Clinical Practice Guideline, No. 262, July 2011. J Obstet Gynaecol Can 33 (2011), 754–767.
25. 25 Dar, P., Curnow, K.J., Gross, S.J., Hall, M.P., Stosic, M., Demko, Z., et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. Am J Obstet Gynecol, 211, 2014, 527.
26. 26 Zhang, H., Gao, Y., Jiang, F., Fu, M., Yuan, Y., Guo, Y., et al. Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146958 pregnancies. Ultrasound Obstet Gynecol 45 (2015), 530–538.
27. 27 Ogbogu, U., Caulfield, T., Science powers commerce: mapping the language, justifications, and perceptions of the drive to commercialize in the context of Canadian research. Can J Comp & Contemp L 1 (2015), 137–158.
28. 28 Agarwal, A., Sayres, L.C., Cho, M.K., Cook-Deegan, R., Chandrasekharan, S., Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn 33 (2013), 521–531.
29. 29 Natera (US). Conceive. Deliver. Available at: http://www.natera.com/reproductive-genetic-testing. Accessed on April 5, 2016.
30. 30 GlobeNewswire. New fetal test spares pregnant moms the risks of amniocentesis. Available at: https://globenewswire.com/news-release/2013/04/03/535659/10027308/en/New-Fetal-Test-Spares-Pregnant-Moms-the-Risks-of-Amniocentesis.html. Accessed on April 15, 2016.
31. 31 Haute Autorité de Santé. Les performances des tests ADN libre circulant pour le dépistage de la trisomy 21 foetale [The performance of free circulating DNA tests for the detection of fetal trisomy 21]. 2015, Haute Autorité de Santé, Saint-Denis, France.
32. 32 United Kingdom National Screening Committee. Consultation for cell-free DNA testing in the first trimester in the Fetal Anomaly Screening Programme. 2016, United Kingdom National Screening Committee, London.
33. 33 Canadian Agency for Drugs and Technologies in Health. Non-invasive prenatal testing: a review of the cost effectiveness and guidelines. 2014, Canadian Agency for Drugs and Technologies in Health, Ottawa.
34. 34 Gekas, J., Langlois, S., Ravitsky, V., Audibert, F., van den Berg, D.G., Haidar, H., et al. Identification of trisomy 18, trisomy 13, and down syndrome from maternal plasma. Appl Clin Genet 7 (2014), 127–131.
35. 35 Piechan, J.L., Hines, K.A., Koller, D.L., Stone, K., Quaid, K., Torres-Martinez, W., et al. NIPT and informed consent: an assessment of patient understanding of a negative NIPT result. J Genet Couns 25:5 (2016), 1127–1137 Accessed April 1, 2016.
36. 36 Sahlin, E., Nordenskjöld, M., Gustavsson, P., Wincent, J., Georgsson, S., Iwarsson, E., Positive attitudes towards non-invasive prenatal testing (NIPT) in a Swedish cohort of 1,003 pregnant women. PloS One, 11, 2016, e0156088.
37. 37 Morris, S., Karlsen, S., Chung, N., Hill, M., Chitty, L.S., Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service. PLoS One, 9, 2014, e93559.
38. 38 Hulstaert, F., Neyt, M., Gyselaers, W., Belgian Health Care Knowledge Center (KCE), The non-invasive prenatal test (NIPT) for trisomy 21 – health economic aspects. Health Technol Assess, 2014 KCE Report 222.
39. 39 Fairbrother, G., Burigo, J., Sharon, T., Song, K., Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. J. Matern Fetal Neonatal Med 29 (2016), 1160–1164.
40. 40 Warren, N., Manderson, L., (eds.) Reframing disability and quality of life: a global perspective, 2013, Springer Science & Business Media, Berlin.
41. 41 Goldhaber-Fiebert, J.D., Brandeau, M.L., Evaluating cost-effectiveness of interventions that affect fertility and childbearing how health effects are measured matters. Med Decis Making 35 (2015), 818–846.
42. 42 Levesque, M., Kim, J.R., Isasi, R., Knoppers, B.M., Joly, Y., Stem cell research funding policies and dynamic innovation: a survey of open access and commercialization requirements. Stem Cell Rev 10 (2014), 455–471.
43. 43 Institute of Medicine, Evolution of translational omics: lessons learned and the path forward. 2012, The National Academies Press, Washington.
44. 44 Roseman, M., Milette, K., Bero, L.A., Coyne, J.C., Lexchin, J., Turner, E.H., et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. J Am Med Assoc 305 (2011), 1008–1017.
45. 45 Lumbreras, B., Parker, L.A., Porta, M., Pollán, M., Ioannidis, J.P.A., Hernández-Aguado, I., Overinterpretation of clinical applicability in molecular diagnostic research. Clin Chem 55 (2009), 786–794.
46. 46 Bell, C.M., Urbach, D.R., Ray, J.G., Bayoumi, A., Rosen, A.B., Greenberg, D., et al. Bias in published cost effectiveness studies: systematic review. Br J Med 332 (2006), 699–703.
47. 47 Petersen, A., Krisjansen, I., Assembling ‘the bioeconomy’: exploiting the power of the promissory life sciences. J Sociol 51 (2015), 28–46.
48. 48 Lundh, A., Sismondo, S., Lexchin, J., Busuioc, O.A., Bero, L., Industry sponsorship and research outcome. Outcome reporting among drug trials registered in ClinicalTrials.gov. Cochrane Database Syst Rev, 12, 2012, MR000033.
49. 49 Fugh-Berman, A., How basic scientists help the pharmaceutical industry market drugs. PLoS Biol, 11, 2013, e1001716.
50. 50 Tsilidis, K.K., Panagiotou, O.A., Sena, E.S., Aretouli, E., Evangelou, E., Howells, D.W., et al. Evaluation of excess significance bias in animal studies of neurological diseases. PLoS Biol, 11, 2013, e1001609.
51. 51 Lexchin, J., Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. Sci Eng Ethics 18 (2012), 247–261.
52. 52 Stamatakis, E., Weiler, R., Ioannidis, J., Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Invest 43 (2013), 469–475.
53. 53 Dachis, B., Chesterley, N., Jacobs, A., Brydon, R., Measuring innovation in Canada: the tale told by patent applications. 2014, C.D. Howe Institute, Toronto, 191 Available at: https://www.cdhowe.org/sites/default/files/attachments/research_papers/mixed/e-brief_191.pdf Accessed on April 15, 2016.
54. 54 Bessen, J., Meurer, M.J., Patent failure. 2008, Princeton University Press, Princeton.
55. 55 Bubela, T.M., Caulfield, T., Role and reality: technology transfer at Canadian universities. Trends Biotechnol 28 (2010), 447–451.
56. 56 Morain, S., Greene, M.F., Mello, M.M., A new era in noninvasive prenatal testing. N Engl J Med 369 (2013), 499–501.
57. 57 MarketersMedia. Non-invasive prenatal testing (NIPT) market expected to reach USD 2.38 billion in 2022: transparency market research. 2015. Available from: http://marketersmedia.com/non-invasive-prenatal-testing-nipt-market-expected-to-reach-usd-2-38-billion-in-2022-transparency-market-research/87584. Accessed on April 15, 2016.
58. 58 PRNewswire. Non-invasive prenatal testing (NIPT) market expected to reach USD 3.68 billion globally in 2019: transparency market research. 2014. Available at: http://www.prnewswire.com/news-releases/non-invasive-prenatal-testing-nipt-market-expected-to-reach-usd-362-billion-globally-in-2019-transparency-market-research-238824411.html. Accessed on April 15, 2016.
59. 59 MarketWatch. Global non-invasive prenatal test (NIPT) market is expected to grow at 17.6% CAGR during 2015-2020. 2015. Available at: http://www.marketwatch.com/story/global-non-invasive-prenatal-testing-nipt-market-is-expected-to-grow-at-176-cagr-during-2015–-2020-2015-11-19-82033153. Accessed on April 15, 2016.
60. 60 Heger M. Sequenom eyes low-risk NIPT market; inks contract with Aetna. GenomeWeb 2014. Available at: https://www.genomeweb.com/sequencing/sequenom-eyes-low-risk-nipt-market-inks-contract-aetna. Accessed on April 15, 2016.
61. 61 Lefkowitz, R.B., Tynan, J.A., Liu, T., Wu, Y., Mazloom, A.R., Almasri, E., et al. Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants. Am J Obstet Gynecol 215 (2016), 227.e1–227.e16.
62. 62 Hui, W.W.I., Chiu, R.W.K., Noninvasive prenatal testing beyond genomic analysis: what the future holds. Curr Opin Obstet Gynecol 28 (2016), 105–110.
63. 63 Regalado A. Prenatal DNA sequencing. MIT Technology Review. 2013. Available at: https://www.technologyreview.com/s/513691/prenatal-dna-sequencing/. Accessed on April 15, 2016.
64. 64 Young RS. A brave new world of prenatal sequencing. MIT Technology Review. 2013. Available at: https://www.technologyreview.com/s/510181/a-brave-new-world-of-prenatal-dna-sequencing/. Accessed on April 15, 2016.
65. 65 Nicolaides, K.H., Syngelaki, A., Ashoor, G., Birdir, C., Touzet, G., Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 207 (2012), 374.e1–374.e6.
66. 66 Bayindir, B., Dehaspe, L., Brison, N., Brady, P., Ardui, S., Kammoun, M., et al. Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management. Eur J Hum Genet 23 (2015), 1286–1293.
67. 67 Straver, R., Oudejans, C.B.M., Sistermans, E.A., Reinders, M.J.T., Calculating the fetal fraction for non invasive prenatal testing based on genome-wide nucleosome profiles. Prenat Diagn 36:7 (2016), 614–621.
68. 68 Dan, S., Wang, W., Ren, J., Li, Y., Hu, H., Xu, Z., et al. Clinical application of massively parallel sequencing-based prenatal noninvasive fetal trisomy test for trisomies 21 and 18 in 11 105 pregnancies with mixed risk factors. Prenat Diagn 32 (2012), 1225–1232.
69. 69 Chen, E.Z., Chiu, R.W., Sun, H., Akolekar, R., Chan, K.A., Leung, T.Y., et al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PloS One, 6, 2011, e21791.
70. 70 Chiu, R.W., Akolekar, R., Zheng, Y.W., Leung, T.Y., Sun, H., Chan, K.A., et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ, 342, 2011, c7401.
71. 71 Chiu, R.W., Chan, K.A., Gao, Y., Lau, V.Y., Zheng, W., Leung, T.Y., et al. Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci USA 105 (2008), 20458–20463.
72. 72 Takoudes, T., Hamar, B., Performance of non-invasive prenatal testing when fetal cell-free DNA is absent. Ultrasound Obstet Gynecol, 45, 2015, 112.
73. 73 Gil, M.M., Quezada, M.S., Revello, R., Akolekar, R., Nicolaides, K.H., Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 45 (2015), 249–266.
74. 74 Lutgendorf, M.A., Stoll, K.A., Why 99% may not be as good as you think it is: limitations of screening for rare diseases. J Matern Fetal Neonat Med 29 (2016), 1187–1189.
75. 75 Thumm, N., Strategic patenting in biotechnology. Technology Analysis & Strategic Management 16 (2004), 529–538.
76. 76 Caulfield, T., Biotechnology and the popular press: hype and the selling of science. Trends Biotechnol 22 (2004), 337–339.
77. 77 Bubela, T.M., Li, M.D., Hafez, M., Bieber, M., Atkins, H., Is belief larger than fact: expectations, optimism and reality for translational stem cell research. BMC Med, 10, 2012, 1.
78. 78 Kamenova, K., Caulfield, T., Stem cell hype: media portrayal of therapy translation. Sci Transl Med, 7, 2015, 278ps4.
79. 79 Bubela, T.M., Caulfield, T., Do the print media “hype” genetic research? A comparison of newspaper stories and peer-reviewed research papers. Can Med Assoc J 170 (2004), 1399–1407.
80. 80 Karow J. Noninvasive prenatal testing diversifies in 2015, migrates toward average-risk market. GenomeWeb 2016. Available at: https://www.genomeweb.com/molecular-diagnostics/noninvasive-prenatal-testing-diversifies-2015-migrates-toward-average-risk. Accessed on April 15, 2016.
81. 81 Norton, M.E., Rink, B.D., Changing indications for invasive testing in an era of improved screening. Semin Perinatol 40 (2016), 56–66.
82. 82 Lo, K.K., Karampetsou, E., Boustred, C., McKay, F., Mason, S., Hill, M., et al. Limited clinical utility of non-invasive prenatal testing for subchromosomal abnormalities. Am J Hum Genet 98 (2016), 34–44.
83. 83 Hill, M., Lewis, C., Chitty, L.S., Stakeholder attitudes and needs regarding cell-free fetal DNA testing. Curr Opin Obstet Gynecol 28 (2016), 125–131.
84. 84 Vanstone, M., King, C., de Vrijer, B., Nisker, J., Non-invasive prenatal testing: ethics and policy considerations. J Obstet Gynaecol Can 36 (2014), 515–526.
85. 85 Lewis, C., Hill, M., Skirton, H., Chitty, L.S., Development and validation of a measure of informed choice for women undergoing non-invasive prenatal testing for aneuploidy. Eur J Hum Genet 24 (2016), 809–816.
86. 86 van Schendel, R.V., Dondorp, W.J., Timmermans, D.R., Hugte, E.J., Boer, A., Pajkrt, E., et al. NIPT-based screening for Down syndrome and beyond: what do pregnant women think?. Prenat Diagn 35 (2015), 598–604.
87. 87 Devaney, S., Palomaki, G., Scott, J., Bianchi, D., Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 306 (2011), 627–636.
88. 88 Stern, A.M., Eugenic nation: faults and frontiers of better breeding in modern America. 2015, University of California Press, Berkeley.
89. 89 Chachkin, C.J., What potent blood: non-invasive prenatal genetic diagnosis and the transformation of modern prenatal care. Am J Law Med 33 (2007), 9–53.
90. 90 Ma, Y., Gong, H., Wen, Y., Nucleic acid-based non-invasive prenatal diagnosis of genetic skin diseases: are we ready?. Exp Dermatol 22 (2013), 392–395.
91. 91 Toews, M., Caulfield, T., Physician liability and non-invasive prenatal testing. J Obstet Gynaecol Can 36 (2014), 907–914.
92. 92 van Schendel, R.V., Kleinveld, J.H., Dondorp, W.J., Pajkrt, E., Timmermans, D.R., Holtkamp, K.C., et al. Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. Eur J Hum Genet 22 (2014), 1345–1350.
93. 93 Farrell, R.M., Mercer, M.B., Agatisa, P.K., Smith, M.B., Philipson, E., It's more than a blood test: patients' perspectives on noninvasive prenatal testing. J Clin Med 3 (2014), 614–631.
94. 94 Canada NewsWire. Medcan is the first Canadian clinic to provide verinata non-invasive prenatal testing (NIPT) to pregnant women. 2013. Available at: http://www.newswire.ca/news-releases/medcan-is-the-first-canadian-clinic-to-provide-verinata-non-invasive-prenatal-testing-nipt-to-pregnant-women-512195581.html. Accessed on April 15, 2016.
95. 95 Press Association. Non-invasive test for Down's syndrome recommended for high-risk women. The Guardian 2016. Available at: http://www.theguardian.com/society/2016/jan/15/non-invasive-test-for-downs-syndrome-recommended-for-high-risk-women. Accessed on April 15, 2016.
96. 96 What to Expect. Noninvasive prenatal testing (NIPT). 2015. Available from: http://www.whattoexpect.com/pregnancy/pregnancy-health/noninvasive-prenatal-testing. Accessed on April 16, 2016.
97. 97 Seavilleklein, V., Challenging the rhetoric of choice in prenatal screening. Bioethics 23 (2009), 68–77.
98. 98 Rothman, B.K., The tentative pregnancy; how amniocentesis changes the experience of motherhood. 1993, WW Norton and Company, New York.
99. 99 Favre, R., Moutel, G., Duchange, N., Vayssière, C., Kohler, M., Bouffet, N., et al. What about informed consent in First-trimester ultrasound screening for Down Syndrome?. Fetal Diagn Ther 23 (2008), 173–184.
100. 100 van den Heuvel, A., Chitty, L., Dormandy, E., Newson, A., Deans, Z., Attwood, S., et al. Will the introduction of non-invasive prenatal diagnostic testing erode informed choices? An experimental study of health care professionals. Patient Educ Couns 78 (2010), 24–28.